Literature DB >> 6114985

Dopamine receptors in the Parkinsonian brain.

U K Rinne, P Lönnberg, V Koskinen.   

Abstract

Striatal dopamine receptors were studied in 44 patients with Parkinson disease by the radioligand-binding technique using 3H-spiroperidol. The specific binding of 3H-spiroperidol was either significantly increased or reduced in the caudate nucleus and putamen of parkinsonian patients without levodopa therapy. Scatchard analysis showed that there were corresponding changes in the receptor number, but no significant changes in the mean dissociation constant. The increased binding of 3H-spiroperidol in the basal ganglia was also found in parkinsonian patients suffering from psychotic episodes and treated with neuroleptic drugs. Normal and low binding of 3H-spiroperidol was found in patients treated with levodopa. Clinically, the patients with low binding were more disabled and had lost the beneficial response to levodopa. Thus in Parkinson disease in some patients a denervation supersensitivity seemed to develop and in some others a loss of postsynaptic dopamine receptor sites in the neostriatum. The latter alteration may contribute to the decreased response of parkinsonian patients to chronic levodopa therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114985     DOI: 10.1007/bf01664007

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  15 in total

1.  Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen
Journal:  Arch Neurol       Date:  1973-02

2.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.

Authors:  D R Burt; I Creese; S H Snyder
Journal:  Science       Date:  1977-04-15       Impact factor: 47.728

3.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease.

Authors:  T Lee; P Seeman; A Rajput; I J Farley; O Hornykiewicz
Journal:  Nature       Date:  1978-05-04       Impact factor: 49.962

4.  Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains.

Authors:  T Lee; P Seeman; W W Tourtellotte; I J Farley; O Hornykeiwicz
Journal:  Nature       Date:  1978-08-31       Impact factor: 49.962

5.  Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.

Authors:  S J List; P Seeman
Journal:  Life Sci       Date:  1979-04-16       Impact factor: 5.037

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

8.  Dopamine-sensitive adenylate cyclase activity in the striatum in Parkinson's disease.

Authors:  M Shibuya
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

9.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15

10.  Increased dopamine-receptor sensitivity in schizophrenia.

Authors:  F Owen; A J Cross; T J Crow; A Longden; M Poulter; G J Riley
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

View more
  11 in total

1.  Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons.

Authors:  M D Neely; D E Schmidt; A Y Deutch
Journal:  Neuroscience       Date:  2007-07-17       Impact factor: 3.590

2.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 3.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

4.  Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.

Authors:  J J Mann; M Stanley; R D Kaplan; J Sweeney; A Neophytides
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

5.  L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.

Authors:  M Guttman; P Seeman
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

6.  Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval.

Authors:  R Castro; P Abreu; C H Calzadilla; M Rodriguez
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

8.  A comparison of brain choline acetyltransferase activity in Alzheimer's disease, multi-infarct dementia, and combined dementia.

Authors:  J O Rinne; E Säkö; L Paljärvi; P K Mölsä; U K Rinne
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

9.  Brain dopamine D-2 receptors in senile dementia.

Authors:  J O Rinne; E Säkö; L Paljärvi; P K Mölsä; U K Rinne
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

Review 10.  mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.

Authors:  Nicolas Morin; Marc Morissette; Laurent Grégoire; Thérèse Di Paolo
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.